Surgery Partners reaffirms 2023 guidance, projects 2024 Adj. EBITDA >$495M

Surgery Partners, Inc.

2023-FY EPS reported -$0.09 revenue$2,743,300,000

Reaffirmed 2023 Adjusted EBITDA guidance of $436M-$440M; revenue ~$2.75B.
Projected 2024 Adjusted EBITDA greater than $495 million, implying ~13% YoY growth.
Guidance based on results through November 2023, subject to year-end adjustments.
Company updated investors at J.P. Morgan Healthcare Conference on January 8, 2024.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surgery Partners, Inc. reported 2023 results: revenue approximately $2.75 billion. Guidance reaffirmed.

Period: 2023
Revenue: approximately $2.75 billion
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surgery Partners, Inc. updated its 2024 guidance (initiated).

Period: 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

In addition, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.

View on SEC.gov

Browse all earnings releases →

Surgery Partners, Inc. filing history →

Source: SEC EDGAR

accession 0001638833-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.